Non-invasive use of inhaled nitric oxide for neonatal pulmonary hypertension
Inhaled nitric oxide (iNO) is a selective pulmonary vasodilator used as primary treatment for babies with persistent pulmonary hypertension of the newborn (PPHN). Evidence shows that its use reduces mortality and need for extracorporeal membrane oxygenation (ECMO).1 iNO is normally commenced at a concentration of 20 parts per million (ppm) when babies have been intubated and ventilated and then slowly weaned off prior to extubation.
Dr Peter ReynoldsConsultant Neonatologist
Gemma Finch
Advanced Neonatal Nurse Practitioner
St Peter’s Hospital, Chertsey
peter.reynolds1@nhs.net
@neonataldoc
Reynolds P., Finch G. Non-invasive use of inhaled nitric oxide for neonatal pulmonary hypertension. Infant 2025; 21(1): 6-7.

Please subscribe and log in to see the full article.
- Minimisation of exposure to invasive ventilation is important.
- Inhaled nitric oxide (iNO) is a selective pulmonary vasodilator used as primary treatment for babies with PPHN.
- Inhaled nitric oxide is used as primary treatment for babies with persistent pulmonary hypertension of the newborn.
- iNO can be given via non-invasive ventilation in certain scenarios.
Also published in Infant:
